A laboratory technician collects vials of patient swabs during coronavirus detection testing at a laboratory
A laboratory technician collects vials of patient swabs during coronavirus detection testing at a laboratory | Photo: Oliver Bunic | Bloomberg
Text Size:

New Delhi: After halting the trials of anti-malarial drug hydroxychloroquine (HCQ), the World Health Organization announced Saturday that it will also discontinue the arm of anti-HIV drugs lopinavir and ritonavir in its Solidarity Trial, after the combo showed little impact on reducing the mortality rate among hospitalised Covid-19 patients.

“WHO today accepted the recommendation from the Solidarity Trial’s International Steering Committee to discontinue the trial’s hydroxychloroquine and lopinavir/ritonavir arms,” WHO said in a statement on 4 July.

The Solidarity Trial was established by the WHO to find an effective Covid-19 treatment for hospitalised patients, and India is also one of the participants of the trial.

This comes just days after the UK’s largest drug trial, RECOVERY, also showed that the lopinavir-ritonavir combination does not have any impact on reducing mortality of hospitalised patients and discontinued its use in its trial.

WHO’s decision was taken by the International Steering Committee — a group of independent experts — after reviewing the evidence from all trials at the WHO Summit on Covid-19 research and innovation on 1 and 2 July.

“These interim trial results show that hydroxychloroquine and lopinavir/ritonavir produce little or no reduction in the mortality of hospitalized COVID-19 patients when compared to standard of care. Solidarity trial investigators will interrupt the trials with immediate effect,” it said.

Also read: Door-to-door Covid survey ‘not suitable’ for entire Delhi: Report calls for change in strategy

We are deeply grateful to our readers & viewers for their time, trust and subscriptions.

Quality journalism is expensive and needs readers to pay for it. Your support will define our work and ThePrint’s future.


Decision applies only to hospitalised patients

The Solidarity Trial conducted in over 35 countries with more than 3,500 patients started with four drugs — hydroxychloroquine, remedesivir, lopinavir/ritonavir and arm of lopinavir/ritonavir with interferon beta-1 a.

WHO had earlier halted the HCQ arm of the trial on 17 June after results of the UK’s RECOVERY trial and a review of other evidence showed the drug did not improve mortality as compared to standard of care in hospitalised patients.

WHO’s recent statement also clarified that the decision only applies to the hospitalised patients and “does not include the possible evaluation of other studies of HCQ and lopinavir/ritonavir in non-hospitalised settings or as pre or post exposure prophylaxis”.

The anti-HIV drug combination of lopinavir and ritonavir is not a part of India’s revised guidelines for management of Covid-19.

However, HCQ, which was shown to be ineffective in reducing mortality in both RECOVERY and WHO’s interim analysis, is still recommended for use in India for mild and moderate patients in early stages of the disease, even in its latest guidelines issued on 3 July.

Meanwhile, the interim Solidarity results are also being readied for peer-reviewed publication, the WHO added.

Also read: Covid is making us forget those with acute and chronic health conditions

Subscribe to our channels on YouTube & Telegram

News media is in a crisis & only you can fix it

You are reading this because you value good, intelligent and objective journalism. We thank you for your time and your trust.

You also know that the news media is facing an unprecedented crisis. It is likely that you are also hearing of the brutal layoffs and pay-cuts hitting the industry. There are many reasons why the media’s economics is broken. But a big one is that good people are not yet paying enough for good journalism.

We have a newsroom filled with talented young reporters. We also have the country’s most robust editing and fact-checking team, finest news photographers and video professionals. We are building India’s most ambitious and energetic news platform. And we aren’t even three yet.

At ThePrint, we invest in quality journalists. We pay them fairly and on time even in this difficult period. As you may have noticed, we do not flinch from spending whatever it takes to make sure our reporters reach where the story is. Our stellar coronavirus coverage is a good example. You can check some of it here.

This comes with a sizable cost. For us to continue bringing quality journalism, we need readers like you to pay for it. Because the advertising market is broken too.

If you think we deserve your support, do join us in this endeavour to strengthen fair, free, courageous, and questioning journalism, please click on the link below. Your support will define our journalism, and ThePrint’s future. It will take just a few seconds of your time.

Support Our Journalism

Share Your Views


Please enter your comment!
Please enter your name here